Evidence Level:Resistant: D – Preclinical
New
Title:
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Excerpt:Chronic treatment of additional BRAFV600E melanoma cell lines with 885 led to the emergence of drug resistance.
DOI:https://doi.org/10.1016/j.ccr.2010.11.023